Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026 Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 19, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quart...
Ardelyx Receives New Patent for Tenapanor New patent covers IBSRELA® and XPHOZAH® and expires in 2042 WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor” with an expiration date of November 26, 2042. The patent relates to the formulation of t...
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the first patient has been dosed in ACCEL (ten-03-301), a Phase 3 clinical trial designed to assess the safety and efficacy of IBSRELA® (tenapanor) for the treatment of chronic idiopathic constipation (CIC) in adults. ACCEL is a multice...
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook Company achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1 IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241 IBSRELA expected to achieve $410-430 million in revenue in 2026 IBSRELA revenue expected to reach $1 billion in 2029 WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.